Tag: GlobeNewswire

FORT WAYNE, Ind., Oct. 29, 2026 (GLOBE NEWSWIRE) — Franklin Electric Co., Inc. (NASDAQ: FELE), a global leader in the manufacturing and distribution of systems, focused on the movement and management of water, fuel and electricity, today announced that CEO Joe Ruzynski and CFO Jennifer Wolfenbarger will participate along with Investor Relations at the following upcoming investor conferences:

• Northcoast Research Fall Management Forum, November 9^th, virtually
• Baird 2026 Global Industrial Conference, November 10^th, Chicago
• Oppenheimer Winter Industrial Summit, December 8^th, virtually

About Franklin Electric
Franklin Electric is a global leader in the production and marketing of systems and components for the movement of water and energy. Recognized as a technical leader in its products and services, Franklin Electric serves customers worldwide in residential, commercial, agricultural, industrial, municipal and fueling applications. Franklin Electric is proud to be recognized in Newsweek’s lists of America’s Most Responsible Companies 2025, Most Trustworthy Companies 2025, and Greenest Companies 2025. 

Franklin Electric uses our Investor Relations website, Investor Relations | Franklin Electric, as a means of disclosing information which may be of interest or material to our investors and for complying with disclosure obligations under Regulation FD. Accordingly, investors should monitor our Investor Relations website, in addition to following our press releases, SEC filings, public conference calls, webcasts, and social media.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein, including those relating to market conditions or the Company’s financial results, costs, expenses or expense reductions, profit margins, inventory levels, foreign currency translation rates, liquidity expectations, business goals and sales growth, involve risks and uncertainties, including but not limited to, risks and uncertainties with respect to general economic and currency conditions, various conditions specific to the Company’s business and industry, weather conditions, new housing starts, market demand, competitive factors, changes in distribution channels, supply constraints, effect of price increases,  raw material costs, technology factors, integration of acquisitions, litigation, government and regulatory actions, the Company’s accounting policies, future trends, epidemics and pandemics, and other risks which are detailed in the Company’s Securities and Exchange Commission filings, included in Item 1A of Part I of the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2025, Exhibit 99.1 attached thereto and in Item 1A of Part II of the Company’s Quarterly Reports on Form 10-Q. These risks and uncertainties may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements made herein are based on information currently available, and the Company assumes no obligation to update any forward-looking statements.

CONTACT:	Jennifer Wolfenbarger / Dean Cantrell
	Franklin Electric Co., Inc.
	260.824.2900

SKNY-1’s Weight Reduction Without Significant Changes in Food Consumption Suggests a Potential Role for Energy Expenditure, Contrasting With Semaglutide’s Initial Food-Intake Suppression and Significant Post-Treatment Increase

MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) — MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral therapeutics, today announced initial positive proof-of-concept results from an exploratory pilot study evaluating SKNY-1, its investigational oral drug candidate for obesity and metabolic disorders.

Conducted in an established diet-induced obesity (DIO) mouse model, the study demonstrated statistically significant reductions in body weight and fat mass following oral administration of SKNY-1 compared with vehicle-treated controls.

Importantly, weight reduction occurred without a statistically significant decrease in food consumption, raising the possibility that SKNY-1 may influence metabolic pathways beyond appetite suppression.

The study also identified three potentially meaningful areas of differentiation from the semaglutide reference group: effects on food intake, lean-mass outcomes, and weight regain following treatment discontinuation. Together, these findings expand upon previous SKNY-1 research and support its continued development as a potentially differentiated oral approach to weight management.

“Obesity represents one of the largest and fastest-growing opportunities in healthcare, with the potential for multiple multibillion-dollar therapies,” said Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals. “We believe the future of obesity treatment will extend beyond a single class of drugs. Patients have different needs, and there is tremendous opportunity for innovative therapies that work through distinct mechanisms and offer favorable profiles for long-term weight management. What makes SKNY-1 particularly exciting is that our findings point toward a potentially differentiated metabolic approach, with encouraging signals regarding body composition and weight maintenance following treatment discontinuation. We believe these characteristics could become important advantages as we continue advancing SKNY-1, positioning it as a potentially valuable asset within our pipeline and an opportunity to participate in this significant global market.”

Key Findings From the SKNY-1 Pilot Study

Statistically Significant Weight and Fat Reduction

Oral SKNY-1 demonstrated statistically significant reductions in body weight and fat mass compared with vehicle-treated controls. The majority of the treatment-associated weight difference was attributable to fat reduction, providing encouraging evidence of SKNY-1’s activity in an established obesity model.

Favorable Lean-Mass Findings Compared With the Semaglutide Reference Group

At the Day 14 body-composition assessment, oral SKNY-1-treated mice did not demonstrate statistically significant lean-mass loss relative to vehicle controls.

In contrast, semaglutide-treated mice demonstrated statistically significant lean-mass loss compared with vehicle-treated controls.

Limited Weight Regain Following Treatment Discontinuation Compared With Semaglutide

During the two-week observation period following treatment cessation, oral SKNY-1-treated mice demonstrated slow and limited weight regain.

In contrast, semaglutide-treated mice experienced rapid and substantial weight rebound, which was accompanied by a statistically significant increase in food consumption relative to vehicle controls, while oral SKNY-1-treated groups showed no statistically significant increase in food consumption.

Investigating a Potentially Differentiated Metabolic Mechanism
The study’s findings raise the possibility that SKNY-1 may influence energy expenditure, energy utilization, or other metabolic pathways involved in weight regulation, rather than relying primarily on appetite suppression.

These observations provide a scientific rationale for investigating SKNY-1’s potentially differentiated metabolic mechanism.

“One of the most intriguing findings from this pilot study is that SKNY-1 produced significant weight reduction without a statistically significant decrease in food consumption,” said Dr. Itzchak Angel, Chief Scientific Advisor of MIRA Pharmaceuticals. “The contrasting observations in lean-mass outcomes and weight regain following treatment discontinuation compared with the semaglutide reference group are also scientifically interesting. Together, these findings raise the possibility that SKNY-1 may influence how the body utilizes energy, potentially offering a differentiated metabolic approach to weight management. These results further expand and confirm previous studies, which have demonstrated increased energy expenditure without changes in food intake.”

“Our next study will investigate this hypothesis more directly through measurements of energy expenditure and other metabolic parameters, while further characterizing SKNY-1’s effects on body composition and weight regulation.”

Continued Development of SKNY-1
MIRA is advancing SKNY-1 through longer-term preclinical studies to further assess weight reduction, body composition and metabolic effects, while continuing its IND-enabling development activities and chemistry, manufacturing and controls (CMC) manufacturing efforts to support future clinical development.

About SKNY-1
SKNY-1 is MIRA Pharmaceuticals’ investigational oral drug candidate being developed for obesity and metabolic disorders. The compound is a cannabinoid analog being investigated for its potential effects on biological pathways involved in metabolic regulation.

Previously published preclinical research in a zebrafish model of obesity demonstrated approximately 30% weight reduction, accompanied by maintenance of whole-body density, reductions in hepatic triglyceride accumulation, and changes in appetite-related signaling.

The latest pilot study in diet-induced obese mice expands this exploratory research into a mammalian obesity model, providing additional evidence of SKNY-1’s potential as an oral therapeutic candidate for obesity.

About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics. The Company’s pipeline includes Ketamir-2 for chemotherapy-induced peripheral neuropathy (CIPN), which has completed Phase 1 and is advancing toward Phase 2a under an active IND; MIRA-55, an investigational oral drug candidate for inflammatory pain; and SKNY-1, an investigational oral drug candidate for obesity. Following scientific review, the U.S. Drug Enforcement Administration has determined that Ketamir-2, MIRA-55, and SKNY-1 are not classified as controlled substances.

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target,” and other words of similar meaning, although not all forward-looking statements include these words. Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, efficacy, anticipated clinical development, commercialization prospects, market opportunity, and future development of MIRA-55, SKNY-1, Ketamir-2, and the Company’s other product candidates.

These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s current beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s subsequent filings with the U.S. Securities and Exchange Commission (“SEC”).

Forward-looking statements contained in this press release speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Investors are cautioned not to place undue reliance on these forward-looking statements. Additional information regarding these and other risks and uncertainties is contained in the Company’s filings with the SEC, including its Annual Report on Form 10-K and subsequent filings, available at www.sec.gov and in the Investors section of the Company’s website at http://www.mirapharmaceuticals.com/. Forward-looking statements should be considered in light of these risks and uncertainties.

Investor and Media Contact
Krystina Quintana
MIRA Pharmaceuticals
info@mirapharma.com 
(786) 432-9792

SUNNYVALE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — GSI Technology, Inc. (Nasdaq: GSIT), the inventor of the Associative Processing Unit (APU), a paradigm shift in artificial intelligence (AI) and high-performance compute processing, providing true compute-in-memory technology, today announced that management will attend the 15^th Annual ROTH Technology Conference on Wednesday, November 18, 2026, at the Hard Rock Hotel in New York, NY. On behalf of the company, Didier Lasserre, Vice President of Sales and Investor Relations, will host one-on-one meetings.

For conference details or to schedule a one-on-one meeting, please contact your ROTH representative. To learn more and submit a registration request, visit www.roth.com/tech2026. GSI Technology’s slide presentation will be available on the company’s website under the Events and Presentations tab: https://ir.gsitechnology.com/events-and-presentations.

ABOUT GSI TECHNOLOGY
GSI Technology is at the forefront of the AI revolution with our groundbreaking APU technology, designed for unparalleled efficiency in billion-item database searches and high-performance computing. GSI’s innovations, Gemini-I® and Gemini-II®, offer scalable, low-power, high-capacity computing solutions that redefine edge computing capabilities. GSI Technology is headquartered in Sunnyvale, California, and has sales offices in the Americas, Europe, and Asia. For more information, please visit www.gsitechnology.com.

Source: GSI Technology, Inc.

Contacts:
Investor Relations
Hayden IR
Kim Rogers
541-904-5075
Kim@HaydenIR.com

Media Relations
Finn Partners for GSI Technology
Ricca Silverio
(415) 348-2724
gsi@finnpartners.com

Company
GSI Technology, Inc.
Douglas M. Schirle
Chief Financial Officer
408-331-9802

• U.S. FDA clears IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria; additional Phase 2 studies planned in food allergy and relapsing multiple sclerosis
• Company expands pipeline through research collaboration of a novel, oral macrocyclic peptide-based neonatal Fc receptor antagonist program from Generian Pharmaceuticals
• Sheila Gujrathi, M.D., appointed Executive Chair of Processa’s Board of Directors
• Cash runway expected to fund operations into the second half of 2029

VERO BEACH, FL, Oct. 29, 2026 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company developing VT-7208, a Bruton’s tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases, today announced continued execution following its acquisition of Vidya Therapeutics (“Vidya”). Progress includes U.S. Food and Drug Administration (FDA) clearance of the investigational new drug (IND) application for a Phase 2 study of VT-7208 in chronic spontaneous urticaria (CSU), expansion of the pipeline through a research collaboration with Generian Pharmaceuticals, and the appointment of Sheila Gujrathi, M.D., as Executive Chair of the Board of Directors.

Processa is advancing VT-7208, a next-generation, CNS-penetrant, once-daily oral BTK inhibitor, across three Phase 2 proof-of-concept programs, including CSU, food allergy and relapsing multiple sclerosis. These programs provide multiple opportunities to evaluate VT-7208 across distinct immune-mediated diseases. The acquisition was accompanied by an approximately $200 million private placement from leading institutional healthcare investors. The Company expects its current cash resources to support operations into the second half of 2029.

“Since the Vidya transaction, we have made great progress in executing our strategy,” said Dr. Gujrathi. “The FDA clearance of the CSU IND is an exciting step toward advancing VT-7208 across three planned Phase 2 programs. At the same time, the Generian collaboration expands our pipeline around another high-value, clinically validated immune target. With funding in place to support these programs, our focus is on disciplined execution and generating the data needed to demonstrate the potential of the portfolio.”

“Sheila has been an invaluable partner to the Board since the Vidya transaction, and her experience building biotechnology companies, advancing clinical programs and creating long-term value makes her well suited to lead the Board through this next phase,” said Justin Yorke, former Chair of the Processa Board of Directors. “We are pleased to have her step into the Executive Chair role as Processa advances its clinical strategy and broader pipeline.”

FDA Clears IND for Phase 2 Study of VT-7208 in CSU

The FDA has cleared the IND application for VT-7208 in CSU, enabling Processa to advance the program into a Phase 2 study in adults with moderate-to-severe disease.

The planned multicenter, randomized, double-blind, placebo-controlled study is expected to enroll approximately 120 adults whose disease is not adequately controlled with H1 antihistamines. The study will evaluate VT-7208 versus placebo over 12 weeks and assess efficacy, safety, tolerability and pharmacologic activity.

CSU is a chronic inflammatory disease characterized by recurrent hives, swelling or both without an identifiable external trigger and affects an estimated 1.6 to 2 million U.S. adults. Despite available therapies, a meaningful proportion of patients remain inadequately controlled, underscoring the need for additional treatment options.

Pipeline Expansion Through Research Collaboration

Processa also announced that it has entered into a research collaboration and exclusive option agreement with Generian Pharmaceuticals, a UPMC Enterprises portfolio company that emerged from the UPMC/University of Pittsburgh ecosystem for breakthrough science, to advance a novel oral macrocyclic peptide-based neonatal Fc receptor (FcRn) antagonist program, further expanding Processa’s immunology pipeline.

The collaboration targets a clinically validated mechanism for treating IgG-mediated autoimmune diseases and supports the companies’ shared strategy of developing differentiated oral therapeutic alternatives to currently available injectable FcRn therapies. The program complements VT-7208 and reflects Processa’s broader strategy to selectively expand its pipeline around clinically validated immune targets, using capital-efficient structures that provide access to novel programs while preserving flexibility as the science matures.

Sheila Gujrathi Appointed Executive Chair

Dr. Gujrathi has been appointed Executive Chair of the Processa Board of Directors. She has served on the Board since Processa’s acquisition of Vidya in June 2026, where she was founder and its executive chair. In this expanded role, she will support the management team on corporate strategy, capital allocation and organizational development.

Dr. Gujrathi is a physician-scientist, biotechnology entrepreneur and drug developer with extensive experience building biotechnology companies and advancing therapies in immunology. Her prior leadership roles include Executive Chair of Ventyx Biosciences, Chair of Turning Point Therapeutics, Chair of ADARx Pharmaceuticals, co-founder and Chief Executive Officer of Gossamer Bio, and Chief Medical Officer of Receptos.

ABOUT PROCESSA PHARMACEUTICALS

Processa Pharmaceuticals is a clinical-stage pharmaceutical company advancing innovative drug candidates through a disciplined, science-driven development strategy. Following the acquisition of Vidya Therapeutics, Processa’s lead program is VT-7208, a Bruton’s tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases. VT-7208 is a potentially best-in-class BTK inhibitor (BTKi) designed to improve on the efficacy and safety of early-generation programs. Processa is developing VT-7208 in three parallel programs: food allergy and chronic spontaneous urticaria (CSU) in immunology, and relapsing multiple sclerosis (RMS) in neurology, where its CNS-penetrant profile addresses an area of high unmet need. With Phase 1 complete, the company intends to advance all three programs toward Phase 2 proof-of-concept studies.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Processa, Vidya, the concurrent private placement financing and the acquisition of Vidya by Processa (the “Transactions”) and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to the company’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the Transactions and the expected effects, perceived benefits or opportunities and related timing with respect to the Transactions; expectations regarding or plans for VT-7208, including its planned clinical trials, research and development programs and the expected timing for key milestones; the potential benefits of VT-7208 and other clinical and preclinical programs; the perceived benefits of the research collaboration and exclusive option agreement with Generian Pharmaceuticals; and expectations regarding the use of proceeds from the concurrent private placement financing and cash runway expectations therefrom, including such proceeds funding the company into the second half of 2029. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “aim,” “strategy,” “target,” “seek,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the company or the Transactions will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those uncertainties and factors described under the heading “Risk Factors” and in the company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “SEC”) on October 5, 2026 , as well as discussions of potential risks, uncertainties, and other important factors included in other filings by the company from time to time, as well as risk factors associated with companies, such as Processa, that operate in the biotechnology industry. Should one or more of these risks or uncertainties materialize, or should any of the company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The company does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in the company.

CONTACTS
Investors
Priyanka Shah
Elephant Head Communications
pshah@elephantheadcommunicationsllc.com

Media
Ryan Flinn
The Grace Group
ryan@gracegroup.us

Drilling continues at D Zone as GoldHaven explores a silver-rich mineralized system sharing key geological characteristics with Coeur Mining’s Silvertip deposit

VANCOUVER, British Columbia, Oct. 29, 2026 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (“GoldHaven” or the “Company”) (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) is pleased to announce that its inaugural 2026 diamond drilling program at its flagship Magno Project in northwestern British Columbia has reached approximately 3,000 metres, with exploration advancing across its high-grade silver-lead-zinc and tungsten targets.

Recent drilling at D Zone has encountered multiple intervals of semi-massive to massive sulphide mineralization, further advancing GoldHaven’s exploration of a silver-lead-zinc system sharing key geological characteristics with Coeur Mining’s Silvertip deposit. Drilling continues across additional targets, with laboratory assays pending.

Highlights

• Over 3,000 metres drilled: GoldHaven reaches a significant milestone in its inaugural 2026 drilling program at Magno, targeting both silver-lead-zinc and tungsten mineralization.
• High-grade historical silver: Previous D Zone drilling reported 7.6 metres grading 240 g/t silver, 4.73% lead and 4.74% zinc.
• High-grade silver surface samples: GoldHaven’s 2025 exploration program returned up to 2,370 g/t silver at Magno and 1,390 g/t silver at Middle D.
• Silvertip geological comparison: Magno exhibits carbonate replacement-style mineralization, including manto and chimney-style features also characteristic of Coeur Mining’s Silvertip deposit.
• Additional massive sulphides intersected: Drill hole GOH26-15 encountered approximately 18.5 metres of massive sulphide and 9 metres of semi-massive sulphide mineralization, with assays pending.

Advancing Silver-Lead-Zinc Exploration at D Zone

Further to the Company’s October 22nd news release, which described four of the first five completed drill holes at Middle D intersecting semi-massive to massive sulphide mineralization, the latest diamond drill hole in this area (GOH26-15) has intersected approximately 18.5 m and 9 m of massive sulphide and semi-massive sulphide mineralization, respectively. This is in addition to the previously announced GOH26-10 and GOH26-13 which encountered cumulative visually identified mineralized intervals of approximately 10.75 metres and 13 metres, respectively, across separate intervals. True widths are unknown.

The mineralization includes visible galena and sphalerite, with drilling continuing to evaluate the geometry and potential continuity of the system. Laboratory assays remain pending.

CEO Commentary:

“Reaching 3,000 metres in our inaugural drill program is an important milestone, but we’re particularly encouraged by the silver-lead-zinc potential emerging at D Zone,” commented Rob Birmingham, President and CEO of GoldHaven.

“Magno shares compelling geological characteristics with Coeur Mining’s Silvertip deposit. With multiple sulphide intersections and assays approaching, we’re excited to further evaluate the potential of this system.”

Figure 1: Ongoing drilling at D Zone, Magno Project, near Highway 37, British Columbia.

GoldHaven’s Magno Project Shares Key Geological Characteristics with Coeur Mining’s Silvertip Deposit

GoldHaven’s Magno Project is situated within the Cassiar Terrane of northern British Columbia, the same regional geological setting that hosts Coeur Mining’s Silvertip silver-lead-zinc deposit, a well-established carbonate replacement deposit (CRD).

Magno exhibits several geological characteristics associated with the Silvertip model, including carbonate-hosted silver-lead-zinc mineralization, manto- and chimney-style replacement features, and multiple mineralized zones. These similarities provide an established exploration framework for evaluating the broader potential of Magno’s polymetallic system.

GoldHaven is integrating modern geophysical data, geological mapping and ongoing drilling to better understand the distribution and potential continuity of mineralization across its more than 37,000-hectare property.

The comparison is geological in nature only. Mineralization at Silvertip is not necessarily indicative of mineralization at Magno, and no mineral resource has been established at D Zone.

Figure 2: Magno project location bordering Coeur’s Silvertip Holdings and Cassiar Gold Corp.

Next Steps

GoldHaven’s near-term exploration activities include:

1. Continuing drilling across additional targets within the D Zone system.
2. Completing laboratory analysis and reporting assay results following QA/QC review.
3. Integrating geological, geochemical and geophysical datasets to evaluate the distribution and potential continuity of mineralization.

The Magno Project covers more than 37,000 hectares in the Cassiar District and hosts multiple exploration targets, including silver-lead-zinc mineralization at D Zone and Magno, together with tungsten-bearing skarn systems at Kuhn and Dead Goat.

Technical Notes

The historical 7.6-metre D Zone intersection has not been independently verified and is not necessarily indicative of current drill results. Previously reported sulphide intervals are cumulative visual downhole measurements from separate intervals, not true widths, and do not establish laboratory assay grades or economic mineralization. Grab samples are selective and are not representative of deposit-wide grades.

Qualified Person
The scientific and technical information in this news release has been reviewed and approved by Raymond Wladichuk, P.Geo., a non-independent Qualified Person under National Instrument 43-101, prior to dissemination.

About GoldHaven Resources Corp.

GoldHaven Resources Corp. is a Canadian junior exploration company focused on advancing highly prospective mineral projects in North and South America. The Company’s flagship asset is the district-scale Magno Project in the Cassiar District of northern British Columbia. GoldHaven also owns the Three Guardsmen copper-gold project in British Columbia and the Copeçal Gold Project in Mato Grosso, Brazil. In addition, the Company holds a portfolio of critical mineral projects in Brazil.

On Behalf of the Board of Directors

Rob Birmingham, Chief Executive Officer

For further information, please contact:
Rob Birmingham, CEO
www.GoldHavenresources.com
info@goldhavenresources.com
Office Direct: (604) 629-8254

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE- Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

This news release contains forward-looking statements and forward-looking information (collectively, “forward looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein including, without limitation, those listed below under the heading “Forward-Looking Statements in This News Release” are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: “believes”, “will”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “may”, “should”, “potential”, “scheduled”, or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that there will be investor interest in future financings, market fundamentals will result in sustained precious metals demand and prices, the receipt of any necessary permits, licenses and regulatory approvals in connection with the future exploration and development of any future projects in a timely manner, the availability of financing on suitable terms for exploration and development of future projects and the Company’s ability to comply with environmental, health and safety laws.

The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors, including, operating and technical difficulties in connection with mineral exploration and development activities, actual results of exploration activities, the estimation or realization of mineral reserves and mineral resources, the inability of the Company to obtain the necessary financing required to conduct its business and affairs, as currently contemplated, the inability of the Company to enter into definitive agreements in respect of possible Letters of Intent, the timing and amount of estimated future production, the costs of production, capital expenditures, the costs and timing of the development of new deposits, requirements for additional capital, future prices of precious metals, changes in general economic conditions, changes in the financial markets and in the demand and market price for commodities, lack of investor interest in future financings, accidents, labour disputes and other risks of the mining industry, delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities, changes in laws, regulations and policies affecting mining operations, title disputes, the inability of the Company to obtain any necessary permits, consents, approvals or authorizations, including by the Exchange, the timing and possible outcome of any pending litigation, environmental issues and liabilities, and risks related to joint venture operations, and other risks and uncertainties disclosed in the Company’s latest interim Management’s Discussion and Analysis and filed with certain securities commissions in Canada. All of the Company’s Canadian public disclosure filings may be accessed via www.sedarplus.ca and readers are urged to review these materials.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements in this news release or incorporated by reference herein, except as otherwise required by law.

Forward-Looking Statements in This News Release

The following statements in this news release constitute forward-looking information:

• Drilling continuing across additional targets within the D Zone system, including evaluation of the geometry and potential continuity of the mineralized system
• The completion of laboratory analysis and the timing of reporting assay results following QA/QC review
• The Company’s plans to integrate geological, geochemical and geophysical datasets to evaluate the distribution and potential continuity of mineralization across the Magno Project
• The silver-lead-zinc potential of the D Zone system and the Company’s plans to further evaluate that potential as assay results are received
• The use of geological similarities with the Silvertip deposit as an exploration framework for evaluating the broader potential of Magno’s polymetallic system

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/92689088-8785-4d0d-996a-9af2f958d947

https://www.globenewswire.com/NewsRoom/AttachmentNg/8ac86514-1b47-4840-9675-777947fe8199

NEWARK, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) — Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the fourth quarter and full fiscal year 2026 ended July 31, 2026.

Fiscal 2026 and Recent Corporate Highlights

• NDA submitted for remibetadex (Trappsol® Cyclo™). On October 28, 2026, Cyclo Therapeutics submitted a New Drug Application (NDA) to the FDA seeking approval of remibetadex for the treatment of Niemann-Pick Disease Type C. The NDA is supported by the Phase 3 TransportNPC™ study, completed in June 2026, which did not meet its primary endpoint in the overall population (p=0.19) but showed 71% slowing of disease progression in a prespecified analysis of patients receiving background miglustat and/or leucine therapy (p=0.046), and by an overall survival analysis versus matched registry controls. The NDA includes a request for a rare pediatric disease priority review voucher.
• MIT license in Alzheimer’s disease. In April 2026, Cyclo entered into an exclusive, worldwide license with the Massachusetts Institute of Technology for the use of hydroxypropyl-β-cyclodextrin in Alzheimer’s disease.
• LipoMedix. In June 2026, an investigator-initiated Phase II trial of Promitil® with radiotherapy in patients with cisplatin-ineligible head and neck cancer was launched in Israel.
• Rafael Medical Devices. Continued the U.S. commercial build-out of the FDA-cleared VECTR™ System, including its regional distributor network.

Rafael Holdings, Inc. Fourth Quarter Fiscal Year 2026 Financial Results

As of July 31, 2026, we had cash and cash equivalents of $22.1 million.

For the three months ended July 31, 2026, we recorded a net loss attributable to Rafael Holdings of $9.2 million, or $0.18 per share, versus a net loss of $12.1 million, or $0.28 per share in the year ago period. The year over year decrease in net loss is largely attributable to a decrease in general and administrative expenses.

Research and development expenses were $7.5 million for each of the three months ended July 31, 2026 and 2025.

General and administrative expenses were $2.4 million for the three months ended July 31, 2026, compared to $5.5 million in the year ago period. The year over year decrease relates to a decrease in payroll, stock-based compensation expense and professional fees.

Rafael Holdings, Inc. Full Fiscal Year 2026 Financial Results

For the twelve months ended July 31, 2026, we recorded a net loss attributable to Rafael Holdings of $29.6 million, or $0.58 per share, versus a net loss of $30.5 million, or $1.04 per share in the year ago period. The year over year decrease in net loss reflects a $4.4 million gain on Cornerstone’s settlements of accounts payable and convertible notes payable and the absence of prior-year unrealized losses on our investment in Cyclo, partially offset by higher research and development expenses following the consolidation of Cyclo Therapeutics in March 2025.

Research and development expenses were $24.3 million for the twelve months ended July 31, 2026, compared to $12.8 million in the year ago period. The year over year increase was primarily attributable to a $13.4 million increase in Cyclo’s research and development expenses in fiscal 2026, as well as an increase in R&D stock-based compensation expense of $0.4 million, offset by decreases in R&D payroll of $1.5 million, and in clinical trial and other expenses of $0.8 million.

General and administrative expenses were $9.7 million for the twelve months ended July 31, 2026, compared to $13.8 million in the year ago period. The decrease of $4.1 million versus the prior year is primarily attributable to decreases in professional fees of $1.3 million, primarily due to merger-related costs in the prior year, stock-based compensation expense of $1.2 million, payroll expense of $0.6 million due to terminations, and other expenses.

About Rafael Holdings, Inc.

Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. Our lead candidate is remibetadex (Trappsol® Cyclo™), for which we have completed a pivotal Phase 3 study in Niemann-Pick Disease Type C (“NPC”) and submitted an NDA to the FDA in October 2026. NPC is a rare, fatal and progressive genetic disorder. We also hold interests in other clinical-stage and early-stage pharmaceutical development companies and an orthopedic-focused medical device company.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; the FDA’s review of our NDA for remibetadex, including whether it will be accepted for filing, granted priority review or approved; our eligibility for and ability to monetize a priority review voucher; plans regarding the further evaluation of clinical data; and the potential of our pipeline. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the risk that the FDA may not accept for filing or approve our NDA, including because the Phase 3 TransportNPC™ study did not meet its primary endpoint in the overall population, our need for additional financing and the substantial doubt about our ability to continue as a going concern, and those disclosed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended July 31, 2026, and our other filings with the SEC.  These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Contact:
Barbara Ryan
barbara.ryan@rafaelholdings.com
(203) 274-2825

RAFAEL HOLDINGS, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
	July 31,
	2026				2025
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	22,074			$	52,769
Prepaid clinical costs		1,839				1,045
Other receivables		—				1,206
Accounts receivable, net of allowance for credit losses of $245 at July 31, 2026 and July 31, 2025		444				627
Inventory		377				281
Prepaid expenses and other current assets		1,083				786
Total current assets		25,817				56,714
Property and equipment, net		1,503				1,596
Non-current prepaid clinical costs		457				1,399
Convertible notes receivable classified as available-for-sale		2,044				1,858
Goodwill		19,939				19,939
Intangible assets, net		863				994
In-process research and development		31,575				31,575
Investments		750				—
Other assets		107				34
TOTAL ASSETS	$	83,055			$	114,109
LIABILITIES AND EQUITY
CURRENT LIABILITIES
Accounts payable	$	7,014			$	6,893
Accrued expenses		2,943				3,304
Convertible notes payable		608				614
Due to related parties, net		355				723
Other current liabilities		67				66
Total current liabilities		10,987				11,600
Accrued expenses, noncurrent		—				3,895
Convertible notes payable, noncurrent		2				78
Deferred income tax liability		43				138
Other liabilities		53				27
TOTAL LIABILITIES	$	11,085			$	15,738
COMMITMENTS AND CONTINGENCIES
EQUITY
Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of July 31, 2026 and July 31, 2025		8				8
Class B common stock, $0.01 par value; 200,000,000 shares authorized, 51,393,279 issued and outstanding (excluding treasury shares of 101,487) as of July 31, 2026, and 50,789,697 issued and outstanding (excluding treasury shares of 101,487) as of July 31, 2025		514				508
Additional paid-in capital		323,438				322,161
Accumulated deficit		(261,898	)			(232,263	)
Treasury stock, at cost; 101,487 Class B shares as of July 31,  2026 and July 31,  2025		(168	)			(168	)
Accumulated other comprehensive income related to unrealized income on available-for-sale securities		544				358
Accumulated other comprehensive income related to foreign currency translation adjustment		3,871				3,787
Total equity attributable to Rafael Holdings, Inc.		66,309				94,391
Noncontrolling interests		5,661				3,980
TOTAL EQUITY		71,970				98,371
TOTAL LIABILITIES AND EQUITY	$	83,055			$	114,109

RAFAEL HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
	Three Months Ended July 31,								Year Ended July 31,
	2026				2025				2026				2025
	(unaudited)
Revenues	$	244			$	350			$	874			$	917
Cost of infusion technology revenue		—				—				—				106
Cost of product revenue		13				19				42				28
G&A expenses		2,444				5,497				9,704				13,781
R&D expenses		7,467				7,547				24,333				12,823
Depreciation and amortization		51				50				204				288
Loss on impairment of goodwill		–				–				–				3,050
Operating Loss		(9,731	)			(12,763	)			(33,409	)			(29,159	)
Interest income		213				467				1,236				1,996
Realized gain on available-for-sale securities		—				—				—				178
Unrealized (loss) gain on investment – Cyclo		—				—				—				(5,144	)
Unrealized (loss) gain on convertible notes receivable, due from Cyclo		—				—				—				(719	)
Interest expense		(6	)			(168	)			(333	)			(658	)
Gain on settlement of accounts payable and convertible notes payable		464				—				4,422				—
Other income		63				236				117				310
Loss before income taxes		(8,997	)			(12,228	)			(27,967	)			(33,196	)
Benefit from taxes		65				174				13				2,553
Consolidated net loss		(8,932	)			(12,054	)			(27,954	)			(30,643	)
Consolidated net loss		(8,932	)			(12,054	)			(27,954	)			(30,643	)
Net income (loss) attributable to noncontrolling interests		244				40				1,681				(123	)
Net loss attributable to Rafael Holdings, Inc.	$	(9,176	)		$	(12,094	)		$	(29,635	)		$	(30,520	)
Loss per share attributable to common stockholders
Basic and Diluted	$	(0.18	)		$	(0.28	)		$	(0.58	)		$	(1.04	)
Weighted average number of shares used in calculation of loss per share – basic and diluted		51,586,276				43,011,360				51,393,118				29,422,221

BOCA RATON, FL , Oct. 29, 2026 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced it will publish its third quarter 2026 financial results and business outlook on its investor relations website at https://defidevcorp.com/earnings on Thursday, November 12, 2026, at approximately 8:00 a.m. Eastern Time.

A video update featuring CEO Joseph Onorati, CFO John Han, and CSO Dan Kang will be uploaded to youtube.com/@DeFiDevCorp on Thursday, November 12, 2026, at approximately 11:00 a.m. Eastern Time. Management will address strategic highlights and take questions submitted in advance by both retail investors and sell-side analysts. Starting on Monday, November 2nd at 8:00 a.m. Eastern Time, all shareholders will be able to submit and upvote questions for DFDV management by visiting here. This Q&A platform will remain open until Wednesday, November 11th at 4:00 p.m. Eastern Time.

For more information, visit defidevcorp.com. To stay up to date with the latest developments and insights, subscribe to our blog.

About DeFi Development Corp.
DeFi Development Corp. (Nasdaq: DFDV) has adopted a treasury policy under which the principal holding in its treasury reserve is allocated to SOL. Through this strategy, the Company provides investors with direct economic exposure to SOL, while also actively participating in the growth of the Solana ecosystem. In addition to holding and staking SOL, DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake. The Company is also engaged across decentralized finance (DeFi) opportunities and continues to explore innovative ways to support and benefit from Solana’s expanding application layer.

The Company is also an AI-powered online platform that connects the commercial real estate industry by providing value-add services and software subscriptions to multifamily and commercial property professionals, as the Company connects the increasingly complex ecosystem that stakeholders have to manage. The Company’s data and software offerings are generally offered on a subscription basis as software as a service.

Investor Contact:
ir@defidevcorp.com

Media Contact:
press@defidevcorp.com

Unify full-funnel strategies—from CTV reach to digital conversions—in one platform with AI-powered workflows, greater transparency, and open MCP integrations

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) — Teads (NASDAQ: TEAD), the omnichannel outcomes platform, today announced the launch of the next generation of Teads Ad Manager (TAM), its unified, end-to-end advertising platform. The platform evolution is designed to help agencies and advertisers connect campaigns across connected TV (CTV) and digital environments, understand campaign impact across the funnel, extend performance across quality media placements, and work more efficiently through AI-assisted workflows.

As daily media consumption reaches an all-time high of 13 hours and 26 minutes per day, and streaming accounts for the majority of television viewership, consumer journeys have become increasingly cross-screen. Despite this shift, media planning, buying, and reporting remain heavily fragmented across disconnected tools, with 53% of marketers struggling to unify measurement across channels for optimization. The latest evolution of TAM solves this by uniting Teads’ premium global supply across CTV and digital with full-funnel measurement and AI workflows. TAM users can seamlessly connect media investments across screens, measure total campaign impact, and work smarter using their preferred AI tools.

“Marketing teams and agencies can no longer afford to manage brand and performance in isolated silos if they want to drive real business growth,” said Remi Cackel, Chief Product Officer at Teads. “By connecting the omnichannel journey in one platform and enabling AI-powered workflows, we’re giving our partners the control, efficiency, and intelligence needed to make every media investment deliver measurable impact.”

“Agencies require technology that simplifies media execution without compromising supply quality or data flexibility,” said Rheece Hemmings, Programmatic Manager at OMD, UK. “TAM’s connected toolset and open AI architecture allow our teams to plan, activate, and optimize cross-screen campaigns in minutes, giving us full visibility into how branding and performance work together to drive client growth.”

Key Platform Innovations
The next evolution of TAM introduces four key platform capabilities:

• Omnichannel Strategies & Full-Funnel Measurement: Activate campaigns against multiple KPIs across CTV and digital within a single workflow and measure how upper-funnel brand activity drives lower-funnel outcomes—like tracking site visits generated by branding campaigns.
• Unified Performance: Extend performance campaigns seamlessly across CTV and digital—including CTV InStream, HomeScreen, inRead, and Feed placements. Access premium, transparent media supply with built-in quality controls and flexible measurement integrations, including Conversion API (CAPI) and Google Analytics 4 (GA4).
• Agentic AI Workflows: Automate campaign planning, setup, management, and reporting with task-specific AI copilots. Go from brief to strategy with Strategy Builder or catch delivery and pacing risks instantly in Control Hub—slashing troubleshooting time from 15 minutes to under 60 seconds.¹
• Open Model Context Protocol (MCP) Interconnectivity: Connect Teads’ audience insights, reach forecasting, and inventory discovery directly into agency AI systems, including Claude, Gemini Enterprise, and Microsoft Copilot, through open, secure MCP integrations.

“MCP is really a game changer because it gives us exactly what we need from discovery through to campaign creation,” said Nami Hamidi, Head of Precision at Havas Media Network Italy. “It combines different data sources with TAM’s knowledge and data to help create the best strategy and media plan, with recommendations on audiences, websites, context and creatives, as well as estimates for CPMs and CTRs.”

Teads is also expanding its Teads Ad Manager Certified Agency Program. This global platform accreditation program provides agency teams with structured training in omnichannel media, performance advertising, and strategic planning. Certified partners gain priority beta access and industry recognition for their platform expertise.

Availability
Unified Performance capabilities are generally available to global enterprise clients today. Full-Funnel Measurement, Strategy Builder, Control Hub, and MCP integrations are currently available in closed beta to TAMbassadors, with broader global access planned through the end of 2026.

To request a platform demonstration, beta access, or learn more about Teads Ad Manager, visit https://www.teads.com/lp/teads-ad-manager/ or contact your Teads representative.

Sources
¹ Alpha Test Results (2026): In-platform AI assistant testing.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to possible or assumed future results of our business, financial condition, results of operations, liquidity, plans and objectives. You can generally identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “guidance,” “outlook,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “foresee,” “potential” or “continue” or the negative of these terms or other similar expressions that concern our expectations, strategy, plans or intentions.

We have based these forward-looking statements largely on our current expectations and projections regarding future events and trends that we believe may affect our business, financial condition and results of operations. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors, including but not limited to: the risk that the new capabilities of Teads Ad Manager, including AI-powered workflows and Open MCP integrations, may not perform as expected, launch on the anticipated timeline, or achieve expected market adoption; the highly competitive nature of the digital, CTV, and streaming advertising markets; and the other important risks described in the section entitled “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed for the year ended December 31, 2025, and our Quarterly Reports on Form 10-Q filed for the quarters ended March 31, 2026, and June 30, 2026, filed with the Securities and Exchange Commission (the “SEC”), which are available on our website at https://investors.teads.com/ and on the SEC’s website at www.sec.gov.

Accordingly, you should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those projected in the forward-looking statements. We undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About Teads
Teads Holding Co. (“Teads”) (Nasdaq: TEAD) is a leading omnichannel advertising platform focused on driving outcomes for brand and performance advertisers across screens. With a focus on meaningful business outcomes for full funnel objectives, Teads drives value by leveraging predictive AI technology to connect quality media, beautiful brand creative, and context-driven addressability and measurement. Teads is directly partnered with more than 10,000 publishers and 20,000 advertisers globally. The company is headquartered in New York, New York, with a global team of around 1,700 people in 30+ countries.

For more information, visit www.teads.com.

Media Contact

press@teads.com

Investor Relations Contact

IR@teads.com

(332) 205-8999

Study Reports Immediate Pain Freedom in 14 of 15 Patients; all Patients Achieved Favorable Pain Outcomes at a Mean Six-Month Follow-Up

Multi-Contact Probe Technology Enabled Mapping and Treatment of Trigeminal Nerve Distributions without Repeated Probe Repositioning

EDEN PRAIRIE, Minn., Oct. 29, 2026 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on the surgical diagnosis and treatment of neurological disorders, today announced the publication of initial clinical results evaluating its OneRF^® Trigeminal Nerve Ablation System in the peer-reviewed journal Pain Management.

The article, “OneRF radiofrequency ablation system for the minimally invasive treatment of trigeminal neuralgia: initial clinical experience,” was published online in October 2026. Authored by Michael D. Staudt, Theresa A. Elder, Marshall T. Holland and David P. Darrow, the retrospective study evaluated 15 patients with medically refractory trigeminal neuralgia treated during the system’s limited market release.

Trigeminal neuralgia causes sudden, severe, electric shock–like facial pain that can interfere with eating, speaking, and other daily activities. For patients whose pain cannot be adequately controlled with medication, percutaneous radiofrequency ablation of the trigeminal nerve offers a minimally invasive treatment option.

Conventional radiofrequency systems typically use a single active tip that must be repositioned to map and treat different trigeminal nerve distributions. OneRF’s thin-film, multi-contact probe allows physicians to perform multiple contact-level mapping and lesioning along a single fixed trajectory without repositioning. The lack of needing to reposition the probe may allow for reduced procedure times, lower number of anesthesia cycles and, most importantly, less discomfort for the patient during the procedure.

Key findings from the published study include*:

• Immediate pain freedom in 93.3% of patients: Fourteen of fifteen patients were pain-free immediately after treatment. The remaining patient experienced partial initial relief and became pain-free approximately one week later.
• Favorable outcomes at follow-up: All 15 patients achieved a good clinical outcome, defined as a Barrow Neurological Institute pain score of I–IIIB, at a mean follow-up of six months.
• Pain freedom without medication: Eight patients, or 53.3%, were pain-free and taking no pain medication at their last follow-up. Six additional patients were pain-free while continuing medication; one had residual pain controlled with medication.
• Mapping and treatment along a fixed trajectory: Contact-level mapping was achieved in every case, and no patient required probe repositioning to map and treat multiple trigeminal distributions.
• No observed off-target lesioning: The authors reported no off-target lesioning, ophthalmic complications, or anesthesia dolorosa.
• Complications: One patient developed a cheek hematoma during needle insertion and repositioning, which was treated with ice and resolved after 1 week; this same patient also developed transient masseter weakness.

“Treating trigeminal neuralgia requires careful localization of the nerve distributions responsible for each patient’s pain,” said Michael D. Staudt, MD, lead author of the publication. “In this initial series, the multi-contact probe allowed us to map and treat those distributions along a single fixed trajectory. The early pain outcomes are encouraging, and longer follow-up will help us understand the durability of relief.”

Dave Rosa, President and Chief Executive Officer of NeuroOne, added, “This publication adds peer-reviewed clinical evidence to our experience with OneRF for trigeminal neuralgia. We are encouraged by the pain relief reported in this initial cohort and by the ability to map and treat multiple nerve distributions without repeated probe repositioning. These findings support continued adoption of the platform and its potential to simplify the treatment workflow.”

The authors emphasized that this was a small, retrospective series without a direct comparison group. Larger studies and longer follow-up are needed to establish long-term durability, comparative effectiveness, and the contribution of contact-specific mapping to patient outcomes.

The publication is available at: https://doi.org/10.1080/17581869.2026.2748288.

About the OneRF^® Trigeminal Nerve Ablation System

The OneRF^® Trigeminal Nerve Ablation System leverages NeuroOne’s proprietary radiofrequency ablation technology and features a multi-contact probe designed to enable stimulation, mapping and ablation during trigeminal neuralgia procedures. The system is designed to streamline procedural workflow by potentially reducing the number of probe repositioning and anesthesia cycles while providing physicians with temperature-monitored radiofrequency ablation.

The NeuroOne OneRF^® Trigeminal Nerve Ablation System is indicated for use in procedures to create radiofrequency lesions for the treatment of pain, or for lesioning nerve tissue for functional neurosurgical procedures.

About NeuroOne

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF^® Ablation System (for brain), and OneRF^® Trigeminal Nerve Ablation System.

NeuroOne has also developed the StereoCED™ platform for targeted intracranial drug delivery, which is currently available for animal research and approved investigational clinical studies. StereoCED™ has not been cleared or approved by the FDA or any other regulatory agency. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding patient outcomes and the potential for lower procedure times, lower number of anesthesia cycles and less discomfort for the patient during the procedure. The distribution agreement does not provide for any guaranteed purchase orders, minimum purchase commitments or guaranteed sales, and there can be no assurance as to the level of sales, if any, that will be generated under the arrangement. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our partnerships may not facilitate the commercialization or market acceptance of our technology; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds; the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks related to our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

Clinician disclosure: Drs. Staudt, Holland and Darrow disclosed consulting relationships with NeuroOne. The publication reported no funding for the paper.

* Disclaimer: This recounts several patients’ experiences and may not be representative of all patient outcomes.

Caution: Federal law restricts this device to sale by or on the order of a physician.

Company Contact:
800-631-4030
ir@nmtc1.com

Investor Relations:
MZ Group – MZ North America
949-491-8235
NMTC@mzgroup.us

Maria Maccecchini, PhD, CEO of Annovis, will join industry panel with pharma leaders and present company updates

MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that Maria Maccecchini, PhD, Founder, President and CEO of Annovis, will participate and present in two industry events in November.

U.S. Biotech Day 2026 | November 16–17, 2026 | Philadelphia, PA

• Panel: “Bridging the Translational Gap: From Discovery Insights to Clinical Proof”, November 16, 9:15–9:45 a.m. ET
• Company showcase: November 16, 10:15–10:30 a.m. ET

At U.S. Biotech Day 2026, Dr. Maccecchini will join a panel of leaders from Pfizer, Merck, Bristol Myers Squibb, Boehringer Ingelheim and other pharmaceutical companies to discuss how discovery-stage insights translate into clinical proof. She will also deliver a company presentation highlighting Annovis’ clinical programs and upcoming milestones.

Pharma Partnering Summit 2026 | November 19–20, 2026 | Boston, MA

• Company presentation: “Restoring Proteostasis in Alzheimer’s and Parkinson’s Diseases with Buntanetap, a Translational Inhibitor of Neurotoxic Proteins”, November 19, 11:25–11:55 a.m. ET

At Pharma Partnering Summit 2026, Dr. Maccecchini will present Annovis’ clinical progress and meet with biotech and pharma representatives.

During both events, Dr. Maccecchini will also hold one-on-one meetings with industry leaders. Attendees interested in scheduling a meeting may do so through each event’s partnering system or by contacting us at ir@annovisbio.com.

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com